Pyxis Oncology Inc (PYXS)
Pyxis Oncology, Inc. is a clinical-stage biotechnology company focused on developing therapies for solid tumors. Its pipeline includes PYX-201, an antibody-drug conjugate in Phase 1 testing for patients with relapsed or refractory solid tumors, and PYX-106, a fully human IgG1 antibody targeting Siglec-15 that is also in Phase 1 development for advanced solid tumors. The company is further advancing PYX-107, a CD40 agonist with anti-cancer activity observed across several cancer indications, which is being studied in Phase 2 for tumor types including soft tissue sarcomas, esophageal and gastroesophageal junction cancers, and pancreatic ductal adenocarcinoma. Pyxis Oncology also has licensing arrangements with Pfizer and Biosion USA, Inc. to support development, manufacture, and commercialization of selected product candidates. Founded in 2018, the company is headquartered in Boston, Massachusetts.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-PYXS
|
$3.44
|
3.2% Upside
|
Fair
|
$8.44
|
153.6% Upside
|
Bargain
|
Fair
|
0.0%
|
November 17, 2026
|
24.3x
|
25.2x
|
277.7 M
|
262.6 M
|
5.9%
|
59.4%
|
-13.6
|
76.5%
|
